Alzamend Neuro, Inc.
Every calculator, already run for ALZN
Open the full toolkit →You have the numbers on ALZN. Get the argument.
A written report on which of these readings actually decide the outcome for Alzamend Neuro, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
1 analysts covering ALZNOwnership & short interest
Insider Trading Activity for ALZN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2…
ALZN — frequently asked
Is ALZN a buy right now?
Wall Street's consensus rating on Alzamend Neuro, Inc. is none across 1 analysts, with a mean price target of $26.00 (+1276% vs. the current $1.89). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Alzamend Neuro, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Alzamend Neuro, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ALZN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Alzamend Neuro, Inc., in minutes. 3 free reports included with every account — no credit card required.